Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles

Journal of Nuclear Medicine

Volumn 53, Issue 3, 2012, Pages 480-487

  Gedda, Lars ^a   Fondell, Amelie ^a   Lundqvist, Hans ^a   Park, John W ^b   Edwards, Katarina ^c,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Auger; HER2; Intercalator; Liposome; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; AUGER ELECTRON EMITTING COMPOUND I 125; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOSOME; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG TARGETING; EXPERIMENTAL STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION ABSORPTION; RADIATION DOSE; RADIOISOTOPE THERAPY; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIPOSOMES; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; SURVIVAL; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863341737     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096891     Document Type: Article

References (21)

1. 125I-iododeoxy-uridine. J Natl Cancer Inst. 1969;43:763-773.
2. Kassis AI. The amazing world of Auger electrons. Int J Radiat Biol. 2004;80:789-803. (Pubitemid 40138140)
3. Chen P, Wang J, Hope K, et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med. 2006;47:827-836. (Pubitemid 46768447)
4. 111In- labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357-1368.
5. 111In- NLS-trastuzumab. J Nucl Med. 2010;51:477-483.
6. Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using Auger electron emitters. J Nucl Med. 2005;46:2097-2103. (Pubitemid 46657459)
7. Fondell A, Edwards K, Ickenstein LM, Sjoberg S, Carlsson J, Gedda L. Nuclisome: a novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging. 2010;37:114-123.
8. 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nucl Med Biol. 2006;33:773-783.
9. Lundqvist H, Stenerlöw B, Gedda L. The Auger effect in molecular targeting therapy. In: Stigbrand T, Carlsson J, Adams GP, eds. Targeted Radionuclide Tumor Therapy. Springer Sciences + Business Media BV; 2008:197-216.
10. 125I-labelled DNA-intercalator. J Drug Target. 2011;19:846-855.
11. Ghirmai S, Mume E, Tolmachev V, Sjoberg S. Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. Carbohydr Res. 2005;340:15-24. (Pubitemid 40023293)
12. Chaires JB, Herrera JE,Waring MJ. Preferential binding of daunomycin to 5′ATCG and 5′ATGC sequences revealed by footprinting titration experiments. Biochemistry. 1990;29:6145-6153. (Pubitemid 20222228)
13. Nielsen UB, Kirpotin DB, Pickering EM, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002;1591:109-118. (Pubitemid 35232074)
14. RADAR - available phantoms. RAdiation Dose Assessment Resource Web site. Available at: http://doseinfo-radar.aifm.it/RADARphan.html. Accessed January 27, 2012
15. Brignole C, Marimpietri D, Gambini C, Allen TM, Ponzoni M, Pastorino F. Development of Fab′ fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett. 2003;197:199-204. (Pubitemid 36860011)
16. Pastorino F, Brignole C, Di Paolo D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 2006;66:10073-10082. (Pubitemid 44672061)
17. 177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res. 2007;67:326-331.
18. 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med. 2009;50:2033-2041.
19. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732-6740. (Pubitemid 44085631)
20. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65:11631-11638. (Pubitemid 41821723)
21. Ferrandina G, Corrado G, Licameli A, et al. Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag. 2010;6:463-483.